H ypertension is a major public health problem in the United States, and it is the leading risk factor for premature death and disability. 1 More than 35 million Americans are afflicted with this disease, at least one third of whom receive antihypertensive drugs at an estimated cost of $2.5 billion per year. 2 Furthermore, hypertension is the most common cause for physician office visits and drug prescriptions. 3 Although various modes of nondrug therapy (especially sodium restriction and weight loss) are usually used first in the treatment of hypertension, drug therapy is also often required. The number of drugs available to treat hypertension has grown in the past 20 years (Table 1 ). In the 1950s, several major categories of antihypertensive agents were introduced into clinical practice, including vasodilators, peripheral neuronal inhibitors (principally the Rauwolfia alkaloids), and the thiazide diuretic agents, the last group perhaps constituting the single greatest contribution to the drug therapy of hypertension. 4 In this decade, insights into the pathophysiology of hypertension are being pro-vided by agents like the angiotensin converting enzyme inhibitors and the calcium channel blockers. This growth in antihypertensive drug therapy reflects a continuing need for more effective, less potentially harmful, and simpler drug regimens. In this report, we examined trends in antihypertensive drug use in the United States from 1973 to 1985.
Patients and Methods
We focused our study on chronic outpatient therapy and omitted studying those drugs used primarily for hypertensive crisis like nitroprusside (Table  1 ). In addition, calcium channel blockers were excluded because, as of January 1986, they were not yet approved by the US Food and Drug Administration for treatment of hypertension, and data through 1985 5 indicated minimal use of these agents for such therapy.
Our source for numbers of prescriptions was the National Prescription Audit (NPA), 6 produced by IMS America, a pharmaceutical research firm. This organization has collected data on dispensed prescriptions from samples of chain and independently owned retail pharmacies in the conterminous United States since 1952. Before 1981, 800 pharmacies were sampled nationally, and dispensed prescription data were sampled manually from their paper files. Since that time, IMS America has used a national panel of 1,200 computerized pharmacies to provide dispensed-prescription data. Although the pharmacies recruited do not represent a probability sample, they are representative of the type of store We grouped NPA data into total numbers of prescriptions for each nonproprietary (generic) ingredient (single-entity and combination products combined) ( Table 2 ). In this article, our use of the term "prescription" refers to each component of a single or combination product. Thus, for example, one actual prescription for Dyazide (Smith Kline & French Laboratories, Philadelphia, Pennsylvania) counts as two, one for its hydrochlorothiazide component and one for its triamterene component.
Another IMS America data base, the National Disease and Therapeutic Index (NDTI), 5 provided patient diagnostic and drug treatment information. To obtain these data, IMS America uses a sample of office-based physicians in the conterminous United States. For 2 consecutive days each quarter, a physician completes a form for each patient contact (whether by telephone, in hospital, or at the office). The physician sampling frame is based on the region of the United States and specialty. IMS America then extrapolates these results to the national level (48 states and the District of Columbia).
IMS America changed its sampling method between 1981 and 1982. The number of participating physicians increased from 1,643 to 2,130, and physicians were able to remain in the sample indefinitely rather than participating for only four consecutive quarters.
For each diagnosis, physicians note the specific drug "mentioned" and indicate how the drug was issued. Information is recorded regarding the method by which the drug was mentioned, that is, dispensed from stock, given as a sample, prescribed by signature or telephone, ordered in the hospital, or only recommended. Thus, mention of a drug on the IMS form does not necessarily mean that a prescription was issued.
Because some antihypertensive drugs are also used for other purposes, the fraction of each generic 
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•Actual values of numbers of prescriptions are x 1,000 of values presented in table. tACE, angiotensin converting enzyme. tMecamylamine is a ganglionic neural blocker. §Pargyline is a monoamine oxidase inhibitor.
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drug's total prescriptions that was mentioned in connection with a hypertensive diagnosis was estimated from NDTI data. First, for each listed brand of each "multipurpose" generic product, we tabulated the fraction of diagnoses that related to hypertension for 1973, 1979, and 1985 . Values for intervening years were estimated through linear interpolation. Then, weighting each brand by its number of prescriptions, we computed each generic drug's average fraction of use for hypertension. Thus, the numbers of prescriptions we report are only for treatment of hypertension.
Results
Overall Trend
During the 13 years studied, total prescriptions for antihypertensive drugs grew from 128.1 to 208.6 million annually, an average increase of 5% per year ( Table 2 ). Diuretic and adrenergic agents accounted for slightly over one half and one third of all prescriptions, respectively, while vasodilators and angiotensin converting enzyme inhibitors accounted for approximately 5% (Table 2) .
Diuretic Agents
While the number of prescriptions for diuretic drugs increased 66% from 1973 (71.1 million) to 1985 (118.3 million), the number of prescriptions for the thiazides, the largest class in this category, increased by 29% (from 54.2 to 69.8 million) ( Table  2) . During this interval, the numbers of prescriptions for potassium-sparing diuretic agents increased fourfold (from 8.1 to 32.6 million), remained relatively unchanged for thiazide-like diuretic drugs (about 9 million), and increased threefold for loopacting diuretic agents (from 2.2 to 7.3 million).
The thiazides accounted for 76% of diuretic prescriptions in 1973 but only 59% in 1985, compared with an increase for potassium-sparing diuretic drugs of 11-28% (Table 2) . Hydrochlorothiazide accounted for 61% of thiazide prescriptions in 1973 compared with 88% in 1985. Hydrochlorothiazide also accounted for one half of all diuretic and one quarter of all antihypertensive prescriptions throughout the study period.
Adrenergic Agents
Changes in the numbers of prescriptions for adrenergic agents were more dynamic (Table 2) , showing an increase of 60% (from 49.4 to 79.1 million) during the 13 years studied. The use of /3-adrenergic receptor blockers grew from 0.9 million prescriptions in 1973 to 37.1 million prescriptions in 1985, a 42-fold increase. In contrast, prescriptions for peripheral neuronal inhibitors decreased threefold (from 32.1 to 10.1 million). Prescriptions for central aadrenergic receptor stimulators increased from 1973 to 1977 and then stabilized at about 24 million. A more modest but steady increase in prescriptions for antihypertensive use of a-adrenergic receptor blockers and combined a-and /3-adrenergic receptor blockers occurred after their release on the market in 1976 and 1984, respectively. /3-Adrenergic receptor blockers accounted for only 2% of adrenergic-agent prescriptions in 1973 but accounted for 47% in 1985 compared with a greater proportional decrease for peripheral neuronal inhibitors (65-13%) ( Table 2) .
Due to the introduction of several new /3-adrenergic receptor blockers since 1978, propranolol accounted for only one third of the prescriptions for /3-adrenergic receptor blockers and only 6% of all prescriptions in 1985 ( Table 2 ). Reserpine accounted for three quarters of all prescriptions within its drug class (peripheral neuronal inhibitors) from 1973 to 1985 and almost one fifth of all prescriptions in 1973, but less than 4% of the total in 1985. Methyldopa accounted for two thirds of prescriptions in its own drug class and a greater fraction of prescriptions for adrenergic agents in 1985 than did propranolol (21% vs. 17%).
Other Antihypertensive Agents
Prescriptions for vasodilators increased from 7.3 to 7.8 million during the study period, but their share of all prescriptions decreased from 6% to 4% (Table  2) . Minoxidil, introduced in 1979, was second to hydralazine in the numbers of prescriptions in this drug class in 1985. Captopril, introduced in 1981 and the sole representative of the angiotensin converting enzyme inhibitors in this study, accounted for less than 2% of all prescriptions in 1985.
The relative ranking of the various drug classes changed from 1973 to 1985 (Table 2 ). The three leading classes of antihypertensive drugs in 1973 were the thiazide diuretic agents, the peripheral neuronal inhibitors, and the central a-adrenergic receptor stimulators. By 1985, the thiazides were still the leader, accounting for almost twice as many prescriptions as the second-ranking /3-adrenergic receptor blockers. Potassium-sparing diuretic drugs were in third place.
The relative ranking of individual antihypertensive drugs does not correlate with their drug class rank. The four leading antihypertensive drugs in 1985 were hydrochlorothiazide, triamterene, methyldopa, and propranolol (Table 2) . /3-Adrenergic receptor blockers accounted for an additional two of the top 10 drugs in 1985 (atenolol, fifth, and metoprolol, sixth).
Discussion
Prescriptions for treatment of hypertension progressively increased during the study period and reflect increasing population exposure to antihypertensive medication. These use trends are consistent with surveys indicating increased drug therapy of hypertension from 1960 to the present. 7 -8 Characteristics of antihypertensive drugs (e.g., expense, age, side effects, and dosage regimen) may relate to the observed trends. Thiazide diuretic drugs continue to be the mainstay of hypertension Supplement I Hypertension Vol 13, No 5, May 1989 treatment because of their efficacy, inexpensiveness, and relatively few side effects. In contrast, among the adrenergic agents, the use of reserpine, the major peripheral neuronal inhibitor, has declined markedly, probably due to its links with cancer and depression and to competition from newer antihypertensive agents.
1 ^-Adrenergic receptor-blocking agents, on the other hand, although not more effective than most of the other adrenergic agents, are generally better tolerated and are the second most widely used antihypertensive drug class after the diuretic agents. 1 Because newer antihypertensive agents, like the angiotensin converting enzyme inhibitors, may have fewer adverse effects on quality of life (measured in such terms as general well-being and work and sexual performance) than some older drugs, 9 these newer agents may make further inroads into the antihypertensive drug market. The place for calcium channel blockers in the treatment of high blood pressure has yet to be determined.
It should be emphasized that our methods included adjustment of drug-use data for the fact that several antihypertensive medications also have other uses. For instance, diuretic drugs may be used for congestive heart failure and other edematous conditions, and the adrenergic agents are of clinical value for the control of cardiac arrhythmias. These medical problems often arise without concomitant hypertension.
These surveys (NPA and NDTI) were designed as marketing tools for the pharmaceutical industry. The samples from which national estimates are extrapolated are relatively small and are subject to potentially important biases. One source of such bias may be the selection of participating physicians. Ideally, each physician in the United States or those within NDTI's specialty-region cells would have an equal likelihood of being selected for participation in the study. Instead, cooperating physicians tend to be retained from one quarter to another. These cooperating physicians may tend to differ from others in their diagnostic or prescribing practices. Another source of bias in the NDTI survey method is the exclusion of certain medical specialties. IMS America indicates that emergency room physicians, who provide a growing component of primary care services like medication refills, are excluded, along with certain other specialties like hematology, immunology, occupational medicine, and oncology.
Although imperfect, these surveys provide extensive information on a continuing basis, extrapolated to national estimates, for patterns of health services and drug use. Thus, we report here on trends in hypertensive drug therapy based on these data but without confidence intervals or other formal quantification of uncertainty. We believe, however, that relatively large and consistent patterns probably reflect real trends in the general medical community.
